登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
FHND9041 Versus Afatinib for Non-small Cell Lung Cancer
ClinicalTrials.gov 上登记的一项肺癌开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT06759857,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 6
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(6 项)收起清单
18 个月 至 未注明;性别:不限
登记记录的入选字段
Histologically or cytologically confirmed diagnosis of locally advanced or metastatic non-small cell lung cancer (NSCLC), including patients with recurrent disease following prior surgical treatment or newly diagnosed Stage IIIb, IIIc, or IV NSCLC (staging based on the 8th edition of the AJCC guidelines).
入选标准第 2 条
No prior systemic anti-tumor therapy (e.g., standard chemotherapy, targeted therapy, biological therapy, or immunotherapy). Patients who have received adjuvant or neoadjuvant therapy (chemotherapy, radiotherapy, or other treatments) are eligible if disease progression occurred at least 6 months after completing the prior treatment.
入选标准第 3 条
Female participants of childbearing potential must have a negative serum pregnancy test prior to enrollment. Male and female participants with reproductive potential must agree to maintain abstinence or use effective contraception during the study and for at least 3 months following the last dose of the investigational drug.
入选标准第 8 条
Unhealed Toxicity: Subjects who have unresolved toxic reactions of grade ≥ 2 (according to NCI-CTCAE 5.0 standards) related to previous treatments, except for hair loss and grade 2 neuropathy caused by platinum-based drugs.
排除标准第 1 条
An Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1.
入选标准第 6 条
Presence of a confirmed EGFR-positive gene mutation sensitive to EGFR-TKI treatment, including exon 19 deletion or L858R mutation.
入选标准第 4 条
Bone Marrow or Organ Dysfunction:Subjects who do not meet the laboratory standards for organ function, including but not limited to: Neutrophil count < 1.5 x 10\^9/L; Platelet count < 90 x 10\^9/L; Hemoglobin < 90 g/L;ALT or AST > 2.5 times the upper limit of normal (ULN), or > 5 times ULN in cases of liver metastasis ;Serum total bilirubin > 1.5 times ULN (or > 3 times ULN if the subject has Gilbert syndrome or liver metastasis); Creatinine > 1.5 times ULN, with a creatinine clearance rate < 50 mL/min (confirmed by Cockcroft-Gault formula, if creatinine is > 1.5 times ULN).
排除标准第 6 条
Lactating Women: Lactating women are excluded from participation.
排除标准第 8 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);影像与可测量病灶;试验排除的其他疾病。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06759857,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Participants aged ≥ 18 years, with no gender restrictions. Histologically or cytologically confirmed diagnosis of locally advanced or metastatic non-small cell lung cancer (NSCLC), including patients with recurrent disease following prior surgical treatment or newly diagnosed Stage IIIb, IIIc, or IV NSCLC (staging based on the 8th edition of the AJCC guidelines). No prior systemic anti-tumor therapy (e.g., standard chemotherapy, targeted therapy, biological therapy, or immunotherapy). Patients who have received adjuvant or neoadjuvant therapy (chemotherapy, radiotherapy, or other treatments) are eligible if disease progression occurred at least 6 months after completing the prior treatment. Presence of a confirmed EGFR-positive gene mutation sensitive to EGFR-TKI treatment, including exon 19 deletion or L858R mutation. At least one measurable tumor lesion at baseline that meets the following criteria: An Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1. A life expectancy of ≥ 3 months. Female participants of childbearing potential must have a negative serum pregnancy test prior to enrollment. Male and female participants with reproductive potential must agree to maintain abstinence or use effective contraception during the study and for at least 3 months following the last dose of the investigational drug. Participants must demonstrate the ability to understand the study objectives and procedures, comply with protocol requirements, cooperate with study-related visits, and provide written informed consent, indicating their voluntary participation.排除标准:Exclusion Criteria:
Unhealed Toxicity: Subjects who have unresolved toxic reactions of grade ≥ 2 (according to NCI-CTCAE 5.0 standards) related to previous treatments, except for hair loss and grade 2 neuropathy caused by platinum-based drugs. Spinal Cord Compression/Brain Metastases: Uncontrolled Systemic Diseases: Subjects with severe or uncontrolled systemic diseases (e.g., hypertension not controlled by medication, active bleeding disorders) that, in the investigator's opinion, may interfere with the participant's ability to comply with the study protocol. Active Infections: Interstitial Lung Disease (ILD): History of interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis requiring steroid treatment, or clinically active ILD. Bone Marrow or Organ Dysfunction:Subjects who do not meet the laboratory standards for organ function, including but not limited to: Neutrophil count < 1.5 x 10\^9/L; Platelet count < 90 x 10\^9/L; Hemoglobin < 90 g/L;ALT or AST > 2.5 times the upper limit of normal (ULN), or > 5 times ULN in cases of liver metastasis ;Serum total bilirubin > 1.5 times ULN (or > 3 times ULN if the subject has Gilbert syndrome or liver metastasis); Creatinine > 1.5 times ULN, with a creatinine clearance rate < 50 mL/min (confirmed by Cockcroft-Gault formula, if creatinine is > 1.5 times ULN). Allergic Reactions: Subjects with a known history of allergy or hypersensitivity to the active ingredients or excipients of the study drug, or to drugs with similar chemical structures to the investigational drug. Lactating Women: Lactating women are excluded from participation. Other Malignant Tumors: Subjects with a history of other malignant tumors, except for those with clinically cured cervical carcinoma in situ, basal cell carcinoma, squamous cell skin cancer, or papillary thyroid carcinoma within the past 5 years. Serious Eye Diseases: Subjects with any serious or uncontrolled eye disease that may increase the safety risk of the investigational drug, as determined by the investigator.
引自 ClinicalTrials.gov, NCT06759857, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06759857,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。